STOCK TITAN

Krystal Biotech Inc - KRYS STOCK NEWS

Welcome to our dedicated news page for Krystal Biotech (Ticker: KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Krystal Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Krystal Biotech's position in the market.

Rhea-AI Summary
Krystal Biotech, Inc. (KRYS) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for VYJUVEK (beremagene geperpavec-svdt, also known as B-VEC) to treat dystrophic epidermolysis bullosa (DEB) in the European Union. The CHMP opinion is expected in the second half of 2024. VYJUVEK has received Orphan Drug Designation, PRIME designation, and a positive opinion from the EMA Pediatric Committee, potentially leading to additional marketing exclusivity in the EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
-
Rhea-AI Summary
Krystal Biotech, Inc. (NASDAQ: KRYS) to participate in Stifel 2023 Healthcare Conference, with Chairman and CEO Krish Krishnan hosting a fireside chat and investor meetings on November 15. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.11%
Tags
conferences
-
Rhea-AI Summary
Krystal Biotech reports $8.6 million in VYJUVEK net product revenue and completion of Phase 1 clinical trials for KB407, first patient dosed in Phase 1 trial for KB707, IND cleared for KB408, and $598.6 million in cash at the end of Q3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.05%
Tags
Rhea-AI Summary
Krystal Biotech, Inc. will report its third quarter 2023 financial results on November 6, 2023, and host an investor conference call at 8:30 am ET to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences earnings
-
Rhea-AI Summary
Krystal Biotech to participate in Chardan 7th Annual Genetic Medicines Conference in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences
-
Rhea-AI Summary
Krystal Biotech receives FDA clearance for IND application of KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
Rhea-AI Summary
Krystal Biotech to participate in Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
conferences
-
Rhea-AI Summary
Krystal Biotech granted Orphan Drug Designation for KB408, a potential treatment for alpha-1 antitrypsin deficiency (AATD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
-
Rhea-AI Summary
Krystal Biotech completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $100 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.63%
Tags
Krystal Biotech Inc

Nasdaq:KRYS

KRYS Rankings

KRYS Stock Data

4.95B
20.55M
12.91%
89.03%
7.62%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Pittsburgh

About KRYS

krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)